Managed Healthcare Executive November 21, 2025
Key Takeaways
- The Medicare Part D and Medicaid pilot program will cover obesity drugs at a $50 copay, but implementation details remain unclear.
- The high wholesale cost of GLP-1 drugs could lead to increased premiums for Part D beneficiaries without substantial manufacturer rebates.
- Direct-to-consumer sales of obesity drugs offer lower prices but raise concerns about patient safety and the role of traditional pharmacy benefit managers.
- Measuring outcomes for obesity drugs is challenging, with skepticism about the program’s ability to demonstrate cost savings and health improvements.
A new Medicare Part D and Medicaid pilot program, expected to begin in April 2026, would provide coverage for certain obesity drugs at a $50 copay for beneficiaries. However, many questions remain about...
Today's Sponsors
Today's Sponsor